Clinical Trials Logo

Glomerulonephritis, IGA clinical trials

View clinical trials related to Glomerulonephritis, IGA.

Filter by:

NCT ID: NCT05942625 Recruiting - IgA Nephropathy Clinical Trials

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

Start date: May 23, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.

NCT ID: NCT05856760 Recruiting - Clinical trials for Immunoglobulin A Nephropathy

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

SPARTACUS
Start date: May 19, 2023
Phase: Phase 2
Study type: Interventional

This is a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry

NCT ID: NCT05852938 Recruiting - IgA Nephropathy Clinical Trials

A Study of BION-1301 in Adults With IgA Nephropathy

Start date: July 27, 2023
Phase: Phase 3
Study type: Interventional

Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy

NCT ID: NCT05847920 Recruiting - Clinical trials for Primary IgA Nephropathy

Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy

Start date: June 4, 2023
Phase: Phase 2
Study type: Interventional

The study is being conducted to evaluate the efficacy, and safety of SHR - 2010 injection in patients with primary IgA nephropathy.

NCT ID: NCT05834738 Recruiting - IgA Nephropathy Clinical Trials

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

ASSIST
Start date: July 20, 2023
Phase: Phase 2
Study type: Interventional

The ASSIST study is a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).

NCT ID: NCT05824390 Active, not recruiting - IgA Nephropathy Clinical Trials

A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy

Start date: June 20, 2020
Phase: Phase 4
Study type: Interventional

A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.

NCT ID: NCT05799287 Recruiting - IgA Nephropathy Clinical Trials

A Study of Telitacicept in Patients With Primary IgA Nephropathy

Start date: April 28, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy.

NCT ID: NCT05797610 Recruiting - Clinical trials for Primary IgA Nephropathy

A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

IMAGINATION
Start date: August 8, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RO7434656, a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.

NCT ID: NCT05797051 Not yet recruiting - Clinical trials for Diabetic Nephropathies

Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases

Start date: May 30, 2023
Phase:
Study type: Observational

Morning urine samples of patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and minimal degenerative nephropathy confirmed by renal needle biopsy in our hospital from November 2020 to January 2022 were collected. By scanning the morning urine samples of corresponding patients with microhyperspectral imager, machine learning and deep learning were used to classify microhyperspectral images, and the classification accuracy was greater than 85%. Thus, hyperspectral imaging technology could be used as a non-invasive diagnostic means to assist the diagnosis of glomerular diseases.

NCT ID: NCT05791162 Recruiting - Clinical trials for Glomerulonephritis, IGA

Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy

LYMFONI
Start date: May 23, 2023
Phase: N/A
Study type: Interventional

This study aims to investigate the relevance of the Tfh/Tfr (Follicular helper T cells/ Follicular regulatory T cells) ratio in patients with IgA nephropathy: - To identify a differential expression of the Tfh/Tfr ratio in patients considered stable or progressive - To predict, at diagnosis, the clinical evolution of the disease (progressive or stable form) in the first year.